When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, our colleague Matthew Herper joins us to pick apart Gilead Sciences’ recent failure in the pervasive liver disease NASH and what it means for the many similar efforts in the pipeline. Then, STAT’s Megan Thielking stops by to talk about what could be the first novel treatment for depression in more than three decades, a ketamine-related drug from Johnson & Johnson (JNJ). Later we hear from Dr. Eric Topol, a cardiologist and geneticist at the Scripps Research Institute in San Diego, about the chasm between hype and reality when it comes to AI in medicine. And then we bring you a lightning round, featuring the latest CRISPR patent drama, 2019’s crop of biotech IPOs, and a new term of art to in the biotech lexicon.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy